Redefining Blood Transfusion at MIOT

Blood transfusion is a life-saving medical procedure. However, what many people may not realise is that there are hidden risks, especially during the early stages of infections that standard screening methods may fail to detect.

At MIOT International, we go beyond conventional protocols to ensure every unit of blood is as safe as possible—protecting every patient who depends on it.

Understanding Standard Blood Screening

As per Ministry of Health (MoH) guidelines, all donated blood undergoes screening using:

  • CMIA (Chemiluminescent Microparticle Immunoassay)
  • A 4th generation test detecting both antigens and antibodies
  • Screening for infections such as:
    • HIV
    • Hepatitis B
    • Hepatitis C

While effective, these methods rely on the body’s immune response, which takes time to develop—creating a “window period” where infections may go undetected.

The Hidden Risk: The Window Period

  • The virus is present in the blood
  • Antibodies/antigens may not yet be detectable
  • This creates a critical gap in detection

This is where traditional testing can miss infections—posing a risk during transfusion.

MIOT’s Advanced Approach: PCR NAT Testing

At MIOT, we implement PCR NAT (Polymerase Chain Reaction – Nucleic Acid Testing) as an advanced layer of screening.

What Makes PCR NAT Different?

  • Detects viral genetic material (DNA/RNA) directly
  • Identifies infections at a much earlier stage
  • Significantly reduces the window period
  • Provides near 100% accuracy in early detection

CMIA vs PCR NAT: A Clear Advantage

Parameter CMIA PCR NAT
Detection Method Antibodies/Antigens DNA/RNA
Stage After immune response Early stage
HIV 23–90 days 8–11 days
HCV 7–14 days 3–5 days
HBV 30–180 days 15–20 days
Accuracy May miss infections Highly accurate
Safety Moderate Maximum safety

Key Takeaway: PCR NAT detects infections earlier and more accurately.

MIOT Blood Bank: Trusted for Safer Blood

  • World-class blood bank with advanced technology
  • 24/7 facility for collection and testing
  • Handles 30,000+ units annually
  • Performs 600+ transfusions every month
  • Follows international safety standards
  • Equipped for emergency and rare blood requirements

Proven Safety Record at MIOT

  • Reaction rates as low as 0.1%
  • Consistent safety outcomes over a decade

Immediate Action. Lives Protected.

At MIOT

    • 2 Hepatitis B–infected blood samples identified early by PCR NAT (missed by CMIA)
    • Each blood unit separated into 4 components (used for 4 patients)

Impact

    • Prevented Hepatitis B transmission to at least 8 patients
    • Ensured safe blood transfusions for all patients